A prominent AI skeptic argues that the industry is a massive bubble, characterized by over a trillion dollars in investment with no demonstrable return. Key companies like OpenAI and Anthropic are described as dangerously unprofitable, with their reported successes attributed to financial engineering rather than sustainable business models.
The conviction of short-seller Andrew Left for manipulating stocks by trading opposite to his public statements highlights the fine line between activist research and illegal activity. The verdict, described as a form of "regulation by jury," creates uncertainty for an industry that has operated in a lightly regulated space.
The discussion moves beyond AI hype to the practical costs of implementation. Examples like Uber capping its AI spending due to budget overruns demonstrate that even major tech companies are struggling to justify the technology's expense against its measurable benefits.
Two distinct stories touch upon the accountability of powerful entities. The first is the successful prosecution of a high-profile market manipulator, while the second involves a controversial agreement granting audit immunity for past tax filings to a former and current presidential candidate.
A startup, Linkgevity, is developing a first-in-class drug to inhibit necrosis, a key mechanism in aging-related diseases. The company has pursued a frugal funding strategy, utilizing grants from government and space agencies to reach a high-value inflection point before seeking major institutional investment for clinical trials.
Keep pulling the thread on Andrew Left.